Skip to content

Effects of Sleep Management on Postoperative Pain in patients after total knee arthroplasty. A randomized controlled study.

Effects of zolpidem tartrate on Postoperative Pain in patients after total knee arthroplasty. A randomized controlled study. - SMAPP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039116
Enrollment
84
Registered
2020-01-15
Start date
2021-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Rheumatoid arthritis

Interventions

Administration of zolpidem tartrate of 5mg for 7 days after surgery No administration of zolpidem tartrate

Sponsors

Mito medical center, Mito Kyodo General Hospital, University of Tsukuba
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patient can understand and comply with the protocol and has signed the informed consent document at screening. 2) Patient is over 20 years old at the time of informed consent. 3) Patient undergoing unilateral total knee arthroplasty 4) Patient assessed by principal and/or co-investigator for eligibility as pain control with multimodal analgesia including femoral and sciatic nerve blocks and PCA fentanyl after TKA surgery.

Exclusion criteria

Exclusion criteria: 1) Patient who has a history or complication of hypersensitivity to celecoxib, fentanyl or sulfonamides, and patient who has a history or complication of a serious allergic reaction to any other drugs. 2) Patient who has a history or complication with aspirin-induced asthma. 3) Patient who has a complication of gastrointestinal hemorrhage or ulcer. 4) Patient who has severe hepatic dysfunction. 5) Patient who has severe renal dysfunction. 6) Patient who has severe cardiovascular dysfunction. 7) Patient who is in a perioperative period of coronary artery bypass surgery. 8) Patient who is pregnant, lactating or probably pregnant. 9) Patient who had a drug abuse. 10) Patient who is judged not to carry the trial through by principal or co-investigator.

Design outcomes

Primary

MeasureTime frame
VAS pain score on the second day after TKA.

Secondary

MeasureTime frame
1. Fentanyl consumption through PCA 2. VAS pain score through the following day to the seventh day after surgery 3. Range of motion of the knee joint 4. Evaluation of sleep quality using VAS sleep disturbance 5. Evaluation of sleep quality including sleep latency, sleep efficacy, nocturnal awakening, sleep depth, body motion and the time it takes to deep sleep monitored by sleep monitor. 6. The overall patient satisfaction during the period of medication. 7. The overall evaluation by physician during the period of medication. 8. Incidence rate of postoperative nausea and vomiting, and frequency of taking anti-nausea pills 9. Rescue analgesic consumption (a diclofenac sodium suppository) after the removal of PCA fentanyl. Study

Countries

Japan

Contacts

Public ContactTakeo Mammoto

Mito medical center, Mito Kyodo General Hospital, University of Tsukuba Department of Orthopaedic Surgery and Sports Medicine

mammototakeo@mitokyodo-hp.jp029-231-2371

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026